Denosumab in patients with cancer-a surgical strike against the osteoclast

Nature Reviews Clinical Oncology

Volumn 9, Issue 2, 2012, Pages 110-118

  Brown, Janet E ^a   Coleman, Robert E ^b  

^a ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^b WESTON PARK HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; AROMATASE INHIBITOR; BISPHOSPHONIC ACID DERIVATIVE; DENOSUMAB; IBANDRONIC ACID; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PAMIDRONIC ACID; PLACEBO; RADIUM CHLORIDE RA 223; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B INHIBITOR; UNCLASSIFIED DRUG; ZOLEDRONIC ACID;

ADVANCED CANCER; ANDROGEN DEPRIVATION THERAPY; BONE CANCER; BONE METASTASIS; BONE NECROSIS; BONE PAIN; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER PREVENTION; CANCER RADIOTHERAPY; CANCER SURVIVAL; CARDIOVASCULAR DISEASE; CASTRATION RESISTANT PROSTATE CANCER; CLINICAL PRACTICE; COLORECTAL CANCER; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG SAFETY; FEVER; GIANT CELL TUMOR; HUMAN; HYPOCALCEMIA; LOADING DRUG DOSE; METASTASIS; MORBIDITY; MULTIPLE MYELOMA; MYALGIA; MYELOMA; NONHUMAN; OSTEOCLAST; OSTEOLYSIS; OVERALL SURVIVAL; POSTMENOPAUSE OSTEOPOROSIS; PRIMARY TUMOR; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN FUNCTION; PROTEIN SYNTHESIS INHIBITION; REVIEW; SINGLE DRUG DOSE; SOLID TUMOR; TREATMENT INDICATION; UNSPECIFIED SIDE EFFECT;

ANTIBODIES, MONOCLONAL; BONE NEOPLASMS; CLINICAL TRIALS AS TOPIC; DIPHOSPHONATES; FRACTURES, BONE; HUMANS; NEOPLASMS; OSTEOCLASTS; RANK LIGAND;

EID: 84862809842     PISSN: 17594774     EISSN: 17594782     Source Type: Journal    
DOI: 10.1038/nrclinonc.2011.197     Document Type: Review

References (59)

1. Lipton, A. New approaches to treating and preventing bone metastases. Curr. Opin. Support. Palliat. Care 4, 178-181 (2010).
2. Coleman, R. E. et al. Metastasis and bone loss; advancing treatment and prevention. Cancer Treat. Rev. 36, 615-620 (2010).
3. Guise, T. Examining the metastatic niche: targeting the microenvironment. Semin. Oncol. 37 (Suppl. 2), S2-S14 (2010).
4. Casimiro, S., Guise, T. A. & Chirgwin, J. The critical role of the bone microenvironment in cancer metastases. Mol. Cell. Endocrinol. 310, 71-81 (2009).
5. Guise, T. A. Brufsky, A. & Coleman, R. E. Understanding and optimizing bone health in breast cancer. Curr. Med. Res. Opin. 26 (Suppl. 3), 3-20 (2010).
6. Coleman, R. E. & McCloskey, E. V. Bisphosphonates in oncology. Bone 49, 71-76 (2011).
7. Boyle, W. J., Simonet, W. S. & Lacey, D. L. Osteoclast differentiation and activation. Nature 423, 337-342 (2003). (Pubitemid 40852708)
8. Kong, Y. Y. et al. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 397, 315-323 (1998).
9. Simonet, W. S. et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 89, 309-319 (1997). (Pubitemid 27199902)
10. Canon, J. R. et al. Inhibition of RANKL blocks skeletal tumor progression and improves survival in a mouse model of breast cancer bone metastasis. Clin. Exp. Metastasis 25, 119-129 (2008).
11. Dougall, W. C. & Chaisson, M. The RANK/RANKL/OPG triad in cancer induced bone diseases. Cancer Metastasis Rev. 25, 541-549 (2006). (Pubitemid 46071863)
12. Kitazawa, S. & Kitazawa, R. RANK ligand is a prerequisite for cancer-associated osteolytic lesions. J. Pathol. 198, 228-236 (2002). (Pubitemid 35243881)
13. Akiyama, T., Choong, P. F. & Dass, C. R. RANK-Fc inhibits malignancy via inhibiting ERK activation and evoking caspase-3-mediated anoikis in human osteosarcoma cells. Clin. Exp. Metastasis 27, 207-215 (2010).
14. Akiyama, T. et al. Systemic RANK-Fc protein therapy is efficacious against primary osteosarcoma growth in a murine model via activity against osteoclasts. J. Pharm. Pharmacol. 62, 470-476 (2010).
15. Mori, K. et al. DU145 human prostate cancer cells express functional receptor of NF?B: new insights in the prostate cancer bone metastasis process. Bone 40, 981-990 (2007). (Pubitemid 46386537)
16. Jones, D. H. et al. Regulation of cancer cell migration and bone metastasis by RANKL. Nature 440, 692-696 (2006).
17. Tan, W. et al. Tumour-infiltrating regulatory T cells stimulate mammary cancer metastasis through RANKL-RANK signalling. Nature 470, 548-553 (2011).
18. Fata, J. E. et al. The osteoclast differentiation factor osteoprotegerin-ligand is essential for mammary gland development. Cell 103, 41-50 (2000).
19. Gonzalez-Suarez, E. et al. RANK ligand mediates progestin-induced mammary epithelial proliferation and carcinogenesis. Nature 468, 103-107 (2010).
20. Schramek, D. et al. Osteoclast differentiation factor RANKL controls development of progestin-driven mammary cancer. Nature 468, 98-102, (2010).
21. Lipton, A. et al. Markers of bone resorption in patients treated with pamidronate. Eur. J. Cancer 34, 2021-2026 (1998). (Pubitemid 28546935)
22. Brown, J. E. et al. Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors. J. Natl Cancer Inst. 97, 59-69 (2005).
23. Coleman, R. E. et al. The predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid. J. Clin. Oncol. 23, 4925-4935 (2005). (Pubitemid 46223998)
24. Body, J. J. et al. A phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases. Cancer 97 (Suppl. 3), 887-892 (2003).
25. Holen, I. et al. Osteoprotegerin (OPG) expression by breast cancer cells in vitro and breast tumours in vivo-a role in tumour cell survival? Breast Cancer Res. Treat. 92, 207-215 (2005). (Pubitemid 41279631)
26. Bekker, P. J. et al. A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL in postmenopausal women. J. Bone Miner. Res. 19, 1059-1066 (2004). (Pubitemid 41110556)
27. Body, J. J. et al. Study of the biological receptor activator of nuclear factor-B ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer. Clin. Cancer Res. 12, 1221-1228 (2006).
28. Lipton, A. et al. Randomized active-controlled phase II study of denosumab efficacy and safety in patients with breast cancer-related bone metastases. J. Clin. Oncol. 25, 4431-4437 (2007). (Pubitemid 350013849)
29. Bone, H. G. et al. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women. J. Clin. Endocrinol. Metab. 93, 2149-2157 (2008). (Pubitemid 351831529)
30. Ellis, G. K. et al. Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for non-metastatic breast cancer. J. Clin. Oncol. 26, 4875-4882 (2008).
31. Oefelein, M. G., Ricchiuti, V., Conrad, W. & Resnick, M. I. Skeletal fractures negatively correlate with overall survival in men with prostate cancer. J. Urol. 168, 1005-1007 (2002).
32. Shahinian, V. B., Kuo, Y. F., Freeman, J. L. & Goodwin, J. S. Risk of fracture after androgen deprivation for prostate cancer. N. Engl. J. Med. 352, 154-164 (2005). (Pubitemid 40096612)
33. Smith, M. R. et al. Risk of clinical fractures after gonadotropin- releasing hormone agonist therapy for prostate cancer. J. Urol. 175, 136-139 (2006). (Pubitemid 41797111)
34. Smith, M. R. et al. Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N. Engl. J. Med. 361, 745-755 (2009).
35. Gnant, M. et al. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial. Lancet Oncol. 12, 631-641 (2011).
36. Coleman, R. E. et al. Breast cancer adjuvant therapy with and without zoledronic acid. N. Engl. J. Med. 365, 1396-1405 (2011).
37. US National Library of Medicine. ClinicalTrials.gov [online] http://clinicaltrials.gov/ct2/show/NCT01077154.
38. Smith, M. R. et al. Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase III, randomised, placebo-controlled trial Lancet http://dx.doi.org/10.1016/S0140-6736(11)61226-9.
39. Fizazi, K. et al. Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates. J. Clin. Oncol. 27, 1564-1571 (2009).
40. Stopeck, A. T. et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J. Clin. Oncol. 28, 5132-5139 (2010).
41. Fizazi, K. et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet 377, 813-822 (2011).
42. Henry, D. H. et al. A randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J. Clin. Oncol. 29, 1125-1132 (2011).
43. Lipton, A., Comparison of denosumab versus zoledronic acid (ZA) for treatment of bone metastases in advanced cancer patients: an integrated analysis of 3 pivotal trials [abstract]. Ann. Oncol. 21 (Suppl. 8), viii380 (2010).
44. Fallowfield, L. et al. Effects of denosumab versus zoledronic acid (ZA) on health-related quality of life (HRQL) in metastatic breast cancer: results from a randomized phase III trial [abstract]. J. Clin. Oncol. 28 (Suppl. 15), a1025 (2010).
45. Heath, D. J. et al. An osteoprotegerin-like peptidomimetic inhibits osteoclastic bone resorption and osteolytic bone disease in myeloma. Cancer Res. 67, 202-208 (2007). (Pubitemid 46142776)
46. Vij, R. et al. An open-label, phase II trial of denosumab in the treatment of relapsed or plateau-phase multiple myeloma. Am. J. Hematol. 84, 650-656 (2009).
47. US National Library of Medicine. ClinicalTrials.gov [online] http://clinicaltrials.gov/ct2/show/NCT01345019.
48. Huang, L., Xu, J., Wood, D. J. & Zheng, M. H. Gene expression of osteoprotegerin ligand, osteoprotegerin, and receptor activator of NF-B in giant cell tumour of bone: possible involvement in tumour cell-induced osteoclast-like cell formation. Am. J. Pathol. 156, 761-767 (2000). (Pubitemid 30626932)
49. Turcotte, R. E., Giant cell tumour of bone. Orthop. Clin. North. Am. 37, 35-51 (2006).
50. Thomas, D. et al. Denosumab in patients with giant-cell tumour of bone: an open-label, phase II study. Lancet Oncol. 11, 275-280 (2010).
51. Saad, F. et al. Incidence, risk factors and outcomes of osteonecrosis of the jaw: integrated analysis from 3 blinded, active-controlled phase III trials in cancer patients with bone metastases. Ann. Oncol. http://dx.doi.org/10.1093/ annonc/mdr435.
52. Ruggiero, S. L. et al. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws-2009 update. J. Oral Maxillofac. Surg. 67 (Suppl. 5), 2-12 (2009).
53. Coleman, R. E. et al. Zoledronic acid. Expert Opin. Drug Saf. 10, 133-145 (2011).
54. Yu, E. Y. et al. Phase II study of dasatinib in patients with metastatic castration resistant prostate cancer. Clin. Cancer Res. 15, 7421-7428 (2009).
55. Gucalp, A. et al. Phase II trial of saracatinib (AZD0530), an oral SRC-inhibitor for the treatment of patients with hormone receptor-negative metastatic breast cancer. Clin. Breast Cancer 5, 306-311 (2011).
56. Nilsson, S. et al. Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled phase II study. Lancet Oncol. 8, 587-594 (2007). (Pubitemid 46995621)
57. Parker, C. et al. Overall survival benefit of radium-223 chloride (Alpharadin) in the treatment of patients with symptomatic bone metastases in castration-resistant prostate cancer (CRPC): a phase III randomised trial (ALSYMPCA) [abstract]. Eur. J. Cancer 47 (Suppl. 2), a3 (2011).
58. Roodman, G. D. Mechanisms of bone metastasis. N. Engl. J. Med. 350, 1655-1664 (2004).
59. Mundy, G. R. Metastasis to bone: causes, consequences and therapeutic opportunities. Nat. Rev. Cancer 2, 584-593 (2002). (Pubitemid 37328925)